Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M710330200 on May 5, 2008

J. Biol. Chem., Vol. 283, Issue 27, 18591-18600, July 4, 2008
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
283/27/18591    most recent
M710330200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Faisal, A.
Right arrow Articles by Parker, P. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Faisal, A.
Right arrow Articles by Parker, P. J.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

The Scaffold MyD88 Acts to Couple Protein Kinase C{epsilon} to Toll-like Receptors*

Amir Faisal{ddagger}, Adrian Saurin{ddagger}, Bernard Gregory§, Brian Foxwell§, and Peter J. Parker{ddagger}1

From the {ddagger}Protein Phosphorylation Laboratory, London Research Institute, Cancer Research UK, London WC2A 3PX, §Kennedy Institute of Rheumatology Division, Faculty of Medicine, Imperial College London, London SW7 2AZ, and King's College London Division of Cancer Studies, Guy's Hospital, London SE1 1UL, United Kingdom

Mice lacking protein kinase C{epsilon} (PKC{epsilon}) are hypersensitive to both Gram-positive and Gram-negative bacterial infections; however, the mechanism of PKC{epsilon} coupling to the Toll-like receptors (TLRs), responsible for pathogen detection, is poorly understood. Here we sought to investigate the mechanism of PKC{epsilon} involvement in TLR signaling and found that PKC{epsilon} is recruited to TLR4 and phosphorylated on two recently identified sites in response to lipopolysaccharide (LPS) stimulation. Phosphorylation at both of these sites (Ser-346 and Ser-368) resulted in PKC{epsilon} binding to 14-3-3β. LPS-induced PKC{epsilon} phosphorylation, 14-3-3β binding, and recruitment to TLR4 were all dependent on expression of the scaffold protein MyD88. In mouse embryo fibroblasts and activated macrophages from MyD88 knock-out mice, LPS-stimulated PKC{epsilon} phosphorylation was reduced compared with wild type cells. Acute knockdown of MyD88 in LPS-responsive 293 cells also resulted in complete loss of Ser-346 phosphorylation and TLR4/PKC{epsilon} association. By contrast, MyD88 overexpression in 293 cells resulted in constitutive phosphorylation of PKC{epsilon}. A general role for MyD88 was evidenced by the finding that phosphorylation of PKC{epsilon} was induced by the activation of all TLRs tested that signal through MyD88 (i.e. all except TLR3) both in RAW cells and in primary human macrophages. Functionally, it is established that phosphorylation of PKC{epsilon} at these two sites is required for TLR4- and TLR2-induced NF{kappa}B reporter activation and I{kappa}B degradation in reconstituted PKC{epsilon}–/– cells. This study therefore identifies the scaffold protein MyD88 as the link coupling TLRs to PKC{epsilon} recruitment, phosphorylation, and downstream signaling.


Received for publication, December 19, 2007 , and in revised form, April 30, 2008.

* The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 To whom correspondence should be addressed: 44 Lincoln's Inn Fields, WC2A 3PX London, UK. Tel.: 44-2072693513; Fax: 44-2072693094; E-mail: peter.parker{at}cancer.org.uk.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2008 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement